Sector News

Trump talks antiviral progress amid COVID-19 pandemic

March 19, 2020
Life sciences

In a much-anticipated press conference Thursday, President Donald Trump said the U.S. has stepped up near-term efforts to advance and make available antivirals to help patients with COVID-19 illnesses.

But despite the urgency and the progress, FDA commissioner Stephen Hahn said it’s important to learn more about all potential treatments.

Amid the pandemic, one drug that’s gained attention in various countries is chloroquine, a decades-old malaria med that’s available for cheap. President Trump said the U.S. is going to make the drug available by prescription “almost immediately.”

Chloroquine is already approved to treat malaria, and Hahn said investigators are planning a “large, pragmatic clinical trial” to learn more. But, the commissioner cautioned, it’s always important to get the “right drug” to the “right patient” at the “right dosage” at the “right time.” The wrong dose could actually hurt a patient’s condition, he added.

While chloroquine isn’t approved for patients with novel coronavirus infections, Trump may have been referencing an off-label use for the medicine. It wasn’t immediately clear how the drug would become available imminently.

Aside from chloroquine, the president and FDA commissioner Hahn talked about efforts to test Gilead’s remdesivir, originally developed for Ebola. Trump said that drug is “very close to approved,” but Hahn declined to specify potential approval timelines.

Coronavirus tracker: Merck CEO calls on Americans to limit contact; FDA halts domestic inspections

Other efforts are underway for plasma-based therapies and repurposing existing medicines, Hahn said at the press conference.

Meanwhile, investigators have launched a vaccine trial “in record time,” the president said. It’ll be 12 months before the study completes and the FDA could potentially approve the shot, Hahn said.

Until then, the antivirals and other drugs are intended to be a “bridge” for treatment until the medical community has a deployable vaccine, Hahn added.

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).